What is your preferred front line regimen for metastatic squamous cell NSCLC that is PD-L1 and driver mutation negative?
How do you select between the available treatment options (gemcitabine, docetaxel, paclitaxel, nab-paclitaxel) in combination with platinum?
Update: KEYNOTE-407 demonstrated improved overall survival with chemo/pembrolizumab vs. chemotherapy alone. How do you now select between the various treatment options?
Community PollStarted
What is your preferred first line tx for metastatic PD-L1/driver mutation negative squamous cell NSCLC in a patient with a good PS?
47 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Henry Ford Cancer Institute/Henry Ford Hospital
Answered on
I believe each are acceptable options. I have generally been using carboplatin and weekly paclitaxel fairly commonly. This regimen is based on Quoix, et al Lancet trial. This study was in elderly patients. I find this very well tolerated with low chances of cytopenias, alopecia. If I have concerns a...
Join for free or sign in to see the full answer